drugset / Trial / NCT06041217

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

NCT06041217

Phase 3 Completed 242 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about 1 year. The participants will have 12 visits at the clinic and 3 remote visits by phone calls with the study doctor or staff.

Timeline

Start
2023-09-15
Primary completion
2025-04-02
Completion
2025-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 2.4 mg Subcutaneous

Indications